SI2331537T1 - 1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamidni derivati kot inhibitorji fosfatidilinozitol 3-kinaze (PI3K), uporabni pri zdravljenju proliferativnih bolezni - Google Patents

1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamidni derivati kot inhibitorji fosfatidilinozitol 3-kinaze (PI3K), uporabni pri zdravljenju proliferativnih bolezni

Info

Publication number: SI2331537T1
Authority: SI; Slovenia
Prior art keywords: heteroarylthiazol; pi3k; phosphatidylinositol; aminocarbonyl; pyrrolidine
Prior art date: 2008-09-10

Application number

SI200931344T

Other languages

English (en)

Inventor

Giorgio Caravatti

Robin Alec Fairhurst

Pascal Furet

Vito Guagnano

Patricia Imbach

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-10

Filing date

2009-09-08

Publication date

2016-02-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40350060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2331537(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-08 Application filed by Novartis Ag filed Critical Novartis Ag

2016-02-29 Publication of SI2331537T1 publication Critical patent/SI2331537T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Psychiatry (AREA)

SI200931344T 2008-09-10 2009-09-08 1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamidni derivati kot inhibitorji fosfatidilinozitol 3-kinaze (PI3K), uporabni pri zdravljenju proliferativnih bolezni SI2331537T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP08164104		2008-09-10
US9667408P	2008-09-12	2008-09-12
EP09782777.8A EP2331537B1 (en)	2008-09-10	2009-09-08	1-((5-heteroarylthiazol-2-yl)aminocarbonyl)pyrrolidine-2-carboxamide derivatives as phosphatidylinositol 3-kinase (pi3k) inhibitors useful in the treatment of proliferative diseases
PCT/EP2009/061644 WO2010029082A1 (en)	2008-09-10	2009-09-08	Organic compounds

Publications (1)

Publication Number	Publication Date
SI2331537T1 true SI2331537T1 (sl)	2016-02-29

Family

ID=40350060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200931344T SI2331537T1 (sl)	2008-09-10	2009-09-08	1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamidni derivati kot inhibitorji fosfatidilinozitol 3-kinaze (PI3K), uporabni pri zdravljenju proliferativnih bolezni

Country Status (50)

Country	Link
US (4)	US8227462B2 (sl)
EP (1)	EP2331537B1 (sl)
JP (1)	JP5486601B2 (sl)
KR (1)	KR101290844B1 (sl)
CN (1)	CN102149711B (sl)
AR (2)	AR073369A1 (sl)
AU (1)	AU2009290904B2 (sl)
BR (1)	BRPI0918750B8 (sl)
CA (1)	CA2734819C (sl)
CL (1)	CL2011000504A1 (sl)
CO (1)	CO6351738A2 (sl)
CR (1)	CR20110059A (sl)
CU (1)	CU24000B1 (sl)
CY (2)	CY1117078T1 (sl)
DK (1)	DK2331537T3 (sl)
DO (1)	DOP2011000070A (sl)
EA (1)	EA018863B1 (sl)
EC (1)	ECSP11010880A (sl)
ES (1)	ES2560673T3 (sl)
FI (1)	FIC20200046I1 (sl)
GE (1)	GEP20135991B (sl)
HN (1)	HN2011000699A (sl)
HR (1)	HRP20160014T1 (sl)
HU (2)	HUE025884T2 (sl)
IL (1)	IL210976A (sl)
JO (1)	JO3121B1 (sl)
LT (1)	LTC2331537I2 (sl)
LU (1)	LUC00186I2 (sl)
MA (1)	MA32604B1 (sl)
ME (1)	ME01284B (sl)
MX (1)	MX2011002597A (sl)
MY (1)	MY151556A (sl)
NI (1)	NI201100049A (sl)
NL (1)	NL301071I2 (sl)
NO (1)	NO2020037I1 (sl)
NZ (1)	NZ590754A (sl)
PA (1)	PA8841901A1 (sl)
PE (1)	PE20110796A1 (sl)
PL (1)	PL2331537T3 (sl)
PT (1)	PT2331537E (sl)
RS (1)	RS54476B1 (sl)
SI (1)	SI2331537T1 (sl)
SM (1)	SMP201100019B (sl)
SV (1)	SV2011003853A (sl)
TN (1)	TN2011000053A1 (sl)
TW (1)	TWI453206B (sl)
UA (1)	UA104147C2 (sl)
UY (1)	UY32096A (sl)
WO (1)	WO2010029082A1 (sl)
ZA (1)	ZA201100699B (sl)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200519106A (en) *	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
JP2011527703A (ja)	2008-07-11	2011-11-04	ノバルティスアーゲー	（ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物
UA104147C2 (uk)	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) *	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
TR201802943T4 (tr) *	2010-11-08	2018-03-21	Novartis Ag	(S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı.
AU2015203865B2 (en) *	2010-11-08	2016-11-03	Novartis Ag	Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
UA112539C2 (uk) *	2011-03-03	2016-09-26	Новартіс Аг	Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
UA110961C2 (uk)	2011-04-25	2016-03-10	Новартіс Аг	КОМБІНАЦІЯ ІНГІБІТОРУ ФОСФАТИДИЛІНОЗИТ-3-КІНАЗИ (PI3K) І ІНГІБІТОРУ mTOR
CN103619840B (zh) *	2011-06-21	2016-01-20	诺华股份有限公司	(s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物
CN103635189B (zh)	2011-07-01	2016-05-04	诺华股份有限公司	用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
WO2013066483A1 (en)	2011-08-31	2013-05-10	Novartis Ag	Synergistic combinations of pi3k- and mek-inhibitors
WO2013049581A1 (en) *	2011-09-30	2013-04-04	Beth Israel Deaconess Medical Center Inc.	Compositions and methods for the treatment of proliferative diseases
BR112014008400A2 (pt) *	2011-10-14	2017-04-04	Novartis Ag	derivados de 2-carboxamida cicloamino ureia em combinação com os inibidores de hsp90 para o tratamento de doenças proliferativas
US20140288073A1 (en) *	2011-10-28	2014-09-25	Novartis Ag	Method of Treating Gastrointestinal Stromal Tumors
MX2014005414A (es) *	2011-11-02	2014-09-22	Novartis Ag	Derivados de 2-carboxamida-cicloamino-urea para su uso en el tratamiento de las enfermedades dependientes del factor de crecimiento endotelial vascular (vegf).
EP2817292B1 (en)	2012-02-22	2019-12-18	Sanford-Burnham Medical Research Institute	Sulfonamide compounds and uses as tnap inhibitors
AR090544A1 (es)	2012-03-29	2014-11-19	Novarits Ag	Metodo para tratar selectivamente a un sujeto que tenga cancer
CA2865993A1 (en) *	2012-03-30	2013-10-03	Novartis Ag	Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma
JP6301316B2 (ja)	2012-05-23	2018-03-28	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
US8980259B2 (en)	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
EP3574904A1 (en)	2012-08-07	2019-12-04	Array Biopharma, Inc.	Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
IN2015DN00528A (sl) *	2012-08-16	2015-06-26	Novartis Ag
AU2013318205B2 (en) *	2012-09-20	2016-05-19	Novartis Ag	Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor\|and an aromatase inhibitor
RU2641913C2 (ru) *	2012-11-16	2018-01-23	Мерк Патент Гмбх	3-аминоциклопентанкарбоксамидные производные
EP3251673A1 (en)	2012-12-13	2017-12-06	IP Gesellschaft für Management mbH	Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
ES2608395T3 (es)	2013-01-23	2017-04-10	Astrazeneca Ab	Compuestos químicos
RU2015143437A (ru)	2013-03-15	2017-04-27	Дженентек, Инк.	Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
SG11201507730UA (en) *	2013-03-21	2015-10-29	Novartis Ag	Combination therapy comprising a b-raf inhibitor and a second inhibitor
CA2908640A1 (en) *	2013-04-05	2014-10-09	Sanofi	Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
WO2014191938A1 (en)	2013-05-31	2014-12-04	Novartis Ag	Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
RU2015156221A (ru) *	2013-06-11	2017-07-17	Новартис Аг	Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки
WO2014203152A1 (en)	2013-06-18	2014-12-24	Novartis Ag	Pharmaceutical combinations
JP2016527305A (ja)	2013-08-08	2016-09-08	ノバルティスアーゲー	Ｐｉｍキナーゼ阻害剤の組合せ
KR20240160682A (ko)	2013-08-14	2024-11-11	노파르티스 아게	암의 치료를 위한 조합 요법
EP3049442A4 (en)	2013-09-26	2017-06-28	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
MX378409B (es)	2013-12-06	2025-03-10	Novartis Ag	Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
RU2016133285A (ru)	2014-01-15	2018-02-20	Новартис Аг	Фармацевтические комбинации
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2937504A1 (en)	2014-02-11	2015-08-20	Novartis Ag	Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
CA2936962C (en)	2014-03-14	2024-03-05	Novartis Ag	Antibody molecules to lag-3 and uses thereof
CA2960824A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies of alk inhibitors
EP3662903A3 (en)	2014-10-03	2020-10-14	Novartis AG	Combination therapies
CN107106497A (zh)	2014-10-03	2017-08-29	诺华股份有限公司	含alpelisib的药物组合物
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964367C (en)	2014-10-14	2024-01-30	Novartis Ag	Antibody molecules to pd-l1 and uses thereof
CN104844589B (zh) *	2014-12-26	2018-04-20	中国科学院合肥物质科学研究院	一种pi3k激酶抑制剂
HK1247089A1 (zh)	2015-03-10	2018-09-21	Aduro Biotech, Inc.	用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
EP3273959A1 (en)	2015-03-25	2018-01-31	Novartis Ag	Pharmaceutical combinations
EP3314265B1 (en)	2015-06-29	2019-07-24	H. Hoffnabb-La Roche Ag	Methods of treatment with taselisib
TW202108592A (zh)	2015-07-02	2021-03-01	瑞士商赫孚孟拉羅股份公司	苯并氧氮呯噁唑啶酮化合物及其用途
WO2017019896A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
CN108348514A (zh)	2015-08-28	2018-07-31	诺华股份有限公司	含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
CN108135905A (zh)	2015-08-28	2018-06-08	诺华股份有限公司	用于治疗癌症的cdk4/6抑制剂lee011、mek1/2抑制剂曲美替尼以及可任选还包括pi3k抑制剂byl719的组合
JP2018528949A (ja)	2015-08-28	2018-10-04	ノバルティスアーゲー	Ｐｉ３ｋ阻害剤およびｍｄｍ２阻害剤を使用する組み合わせ療法
CN108348513A (zh)	2015-08-28	2018-07-31	诺华股份有限公司	用于治疗或预防癌症的ribociclib与达拉菲尼的组合
CA2992221C (en)	2015-08-28	2023-06-27	Novartis Ag	Mdm2 inhibitors and combinations thereof
US20180256557A1 (en)	2015-08-28	2018-09-13	Giordano Caponigro	Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
TW201726140A (zh)	2015-09-17	2017-08-01	瑞典商阿斯特捷利康公司	治療癌症之新型生物標記及方法
CN105294546B (zh) *	2015-10-29	2017-12-08	天津市斯芬克司药物研发有限公司	一种吡啶化合物及其制备方法
WO2017077445A1 (en)	2015-11-02	2017-05-11	Novartis Ag	Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
BR112018008891A8 (pt)	2015-11-03	2019-02-26	Janssen Biotech Inc	anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
EP3383391A1 (en)	2015-12-03	2018-10-10	Novartis AG	Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna
WO2017106656A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Antibody molecules to pd-1 and uses thereof
US11098077B2 (en)	2016-07-05	2021-08-24	Chinook Therapeutics, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018060833A1 (en)	2016-09-27	2018-04-05	Novartis Ag	Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018092064A1 (en)	2016-11-18	2018-05-24	Novartis Ag	Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN106674200B (zh) *	2016-12-21	2019-04-12	西安交通大学	一种含有l-脯氨酰胺片段的化合物及其制备方法和应用
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
MY204117A (en)	2017-06-22	2024-08-08	Novartis Ag	Antibody molecules to cd73 and uses thereof
US20200172628A1 (en)	2017-06-22	2020-06-04	Novartis Ag	Antibody molecules to cd73 and uses thereof
WO2019073031A1 (en)	2017-10-13	2019-04-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	POLYTHERAPY OF PANCREATIC CANCER
WO2019101871A1 (en)	2017-11-23	2019-05-31	Inserm (Institut National De La Sante Et De La Recherche Medicale)	A new marker for predicting the sensitivity to pi3k inhibitors
US10695333B2 (en)	2017-12-01	2020-06-30	Novartis Ag	Pharmaceutical combination comprising LSZ102 and alpelisib
CA3085006A1 (en) *	2017-12-08	2019-06-13	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
RS63124B1 (sr)	2018-03-08	2022-05-31	Incyte Corp	Aminopirazin diol jedinjenja kao pi3k-y inhibitori
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
JP7456945B2 (ja)	2018-05-30	2024-03-27	江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司	三環式誘導体を含む阻害剤、その製造方法、及び使用
US20210214459A1 (en)	2018-05-31	2021-07-15	Novartis Ag	Antibody molecules to cd73 and uses thereof
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
EP3849545A1 (en) *	2018-09-10	2021-07-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for the treatment of neurofibromatosis
CA3115103A1 (en)	2018-10-05	2020-04-09	Sloan-Kettering Institute For Cancer Research	Pi3k inhibitors and uses thereof
CN113195000A (zh)	2018-12-21	2021-07-30	第一三共株式会社	抗体-药物缀合物和激酶抑制剂的组合
EP3971175A4 (en)	2019-05-13	2022-11-09	Luoxin Healthcare Science and Technology Development (Beijing) Ltd.	CRYSTAL FORM OF A QUINAZOLINONE COMPOUND AND PROCESS FOR THEIR PRODUCTION
CN120172965A (zh) *	2019-05-27	2025-06-20	君实润佳(上海)医药科技有限公司	含有稳定重同位素的酰胺官能团的化合物及其应用
WO2021001426A1 (en)	2019-07-02	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of ultrafast elasticity imaging for detecting pancreatic cancers
WO2021001431A1 (en)	2019-07-02	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer
EP3993786A1 (en)	2019-07-02	2022-05-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
KR20220034129A (ko)	2019-07-07	2022-03-17	올레마 파마슈티컬스 인코포레이티드	에스트로겐 수용체 길항제 요법
MX2022002415A (es)	2019-08-26	2022-03-22	Arvinas Operations Inc	Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
AU2020389670A1 (en)	2019-11-25	2022-05-19	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof
CN113045564B (zh) *	2019-12-27	2024-09-20	上海天慈国际药业有限公司	一种阿培利司的制备方法
US11970490B2 (en)	2020-03-25	2024-04-30	Risen (Suzhou) Pharma Tech Co., Ltd.	Stable heavy isotopes in amide functional groups and uses thereof
WO2022016420A1 (zh) *	2020-07-22	2022-01-27	罗欣药业(上海)有限公司	一种喹唑啉酮类化合物的晶型、其制备方法及应用
CN117279627A (zh)	2021-05-03	2023-12-22	诺华股份有限公司	阿培利司配制品
CN115611883B (zh) *	2021-07-13	2025-03-28	生物岛实验室	一种双环结构的PI3Kα抑制剂及其制备方法和用途
EP4431508A1 (en) *	2021-11-12	2024-09-18	Biopolar Youtang (Guangdong) Pharmaceutical Co., Ltd.	Drak2 inhibitor, and preparation method therefor and use thereof
EP4230196A1 (en)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Compounds for use in the treatment of dystrophinopathies
AU2023366352A1 (en)	2022-10-28	2025-05-08	Assistance Publique – Hopitaux De Paris (Aphp)	New inhibitors of phosphatidylinositol 3-kinase
WO2024100236A1 (en)	2022-11-11	2024-05-16	Astrazeneca Ab	Combination therapies for the treatment of cancer
CN116239591B (zh) *	2023-02-14	2025-09-23	嘉兴大学	一种(4r)-磺酰氨基-l-脯氨酰胺类化合物、制备方法、应用及其药物组合
TW202440096A (zh)	2023-03-24	2024-10-16	美商亞文納營運公司	雌激素受體降解劑之給藥方案
CN116987072A (zh) *	2023-07-27	2023-11-03	武汉呈瑞生物医药科技有限公司	化合物及其应用
WO2025181153A1 (en)	2024-03-01	2025-09-04	F. Hoffmann-La Roche Ag	Use of atr inhibitors in combination with pi3k alpha inhibitors
EP4643858A1 (en) *	2024-04-29	2025-11-05	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical composition for the treatment of uterine disease

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4649146A (en) *	1983-01-31	1987-03-10	Fujisawa Pharmaceutical Co., Ltd.	Thiazole derivatives and pharmaceutical composition comprising the same
DE3703435A1 (de)	1987-02-05	1988-08-18	Thomae Gmbh Dr K	Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ATE107280T1 (de)	1988-04-15	1994-07-15	Taiho Pharmaceutical Co Ltd	Carbamoyl-2-pyrrolidinonverbindungen.
US5028726A (en) *	1990-02-07	1991-07-02	The University Of Vermont And State Agricultural College	Platinum amine sulfoxide complexes
US5780653A (en) *	1995-06-07	1998-07-14	Vivorx Pharmaceuticals, Inc.	Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
EP0946587A2 (en)	1996-12-16	1999-10-06	Fujisawa Pharmaceutical Co., Ltd.	New amide compounds
US6187797B1 (en) *	1996-12-23	2001-02-13	Dupont Pharmaceuticals Company	Phenyl-isoxazoles as factor XA Inhibitors
IL130827A0 (en) *	1997-02-10	2001-01-28	Genentech Inc	Heregulin variants
WO1999021555A2 (en)	1997-10-27	1999-05-06	Takeda Chemical Industries, Ltd.	Adenosine a3 receptor antagonists
EP1087951B9 (en)	1998-06-18	2006-09-13	Bristol-Myers Squibb Company	Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
CN1390215A (zh) *	1999-09-10	2003-01-08	麦克公司	酪氨酸激酶抑制剂
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
IL151946A0 (en) *	2000-03-29	2003-04-10	Cyclacel Ltd	2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
EP1506962B1 (en)	2000-10-20	2008-07-02	Eisai R&D Management Co., Ltd.	Nitrogen-containing aromatic heterocycles
EP1256578B1 (en)	2001-05-11	2006-01-11	Pfizer Products Inc.	Thiazole derivatives and their use as cdk inhibitors
NZ530950A (en) *	2001-08-13	2006-03-31	Janssen Pharmaceutica Nv	2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
WO2003015778A1 (en)	2001-08-17	2003-02-27	Merck & Co., Inc.	Tyrosine kinase inhibitors
IL161092A0 (en) *	2001-09-28	2004-08-31	Cyclacel Ltd	N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds
AR038703A1 (es) *	2002-02-28	2005-01-26	Novartis Ag	Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
NZ540161A (en) *	2002-10-30	2008-03-28	Vertex Pharma	Compositions useful as inhibitors of rock and other protein kinases
US7632858B2 (en)	2002-11-15	2009-12-15	Bristol-Myers Squibb Company	Open chain prolyl urea-related modulators of androgen receptor function
AU2004204778B2 (en) *	2003-01-10	2008-05-22	Threshold Pharmaceuticals, Inc.	Treatment of cancer with 2-deoxyglucose
GB0305152D0 (en)	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
TW200519106A (en) *	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
GB0320197D0 (en) *	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
CN1898221A (zh)	2003-09-06	2007-01-17	沃泰克斯药物股份有限公司	Atp－结合弹夹转运蛋白的调控剂
US8802861B2 (en)	2004-01-12	2014-08-12	Merck Serono Sa	Thiazole derivatives and use thereof
MXPA06015237A (es) *	2004-06-29	2007-12-10	Amgen Inc	Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
SE0402735D0 (sv) *	2004-11-09	2004-11-09	Astrazeneca Ab	Novel compounds
HUE038768T2 (hu) *	2005-02-18	2018-11-28	Abraxis Bioscience Llc	Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
DE102005024157A1 (de)	2005-05-23	2006-11-30	Amedo Gmbh	Nadelpositioniersystem
EA014350B1 (ru)	2005-05-24	2010-10-29	Мерк Сероно С.А.	Производные тиазола и их применение
EP1888546B1 (en)	2005-05-24	2015-07-08	Merck Serono SA	Thiazole derivatives and use thereof
DE102005024790A1 (de)	2005-05-26	2006-12-07	Eos Gmbh Electro Optical Systems	Strahlungsheizung zum Heizen des Aufbaumaterials in einer Lasersintervorrichtung
US7655446B2 (en) *	2005-06-28	2010-02-02	Vertex Pharmaceuticals Incorporated	Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof
DE102005048072A1 (de)	2005-09-24	2007-04-05	Bayer Cropscience Ag	Thiazole als Fungizide
JP2009519346A (ja)	2005-12-12	2009-05-14	ジェネラブズテクノロジーズインコーポレーティッド	Ｎ−（５員芳香族環）−アミド抗ウイルス化合物
GB0525671D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
US20090029997A1 (en) *	2006-01-23	2009-01-29	Laboratoires Serono Sa	Thiazole Derivatives and Use Thereof
US20070259855A1 (en) *	2006-04-06	2007-11-08	Udo Maier	Thiazolyl-dihydro-indazole
WO2007129044A1 (en) *	2006-05-03	2007-11-15	Astrazeneca Ab	Thiazole derivatives and their use as anti-tumour agents
GB0610243D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
GB0612630D0 (en) *	2006-06-26	2006-08-02	Novartis Ag	Organic compounds
FR2904190B1 (fr)	2006-07-25	2008-12-12	Inst Rech Pour Le Dev I R D Et	Utilisation d'inocula fongiques pour l'amelioration de la production maraichere
JP2010510246A (ja)	2006-11-21	2010-04-02	スミスクラインビーチャムコーポレーション	アミド抗ウイルス化合物
WO2008124000A2 (en)	2007-04-02	2008-10-16	Ligand Pharmaceuticals Incorporated	Thiazole derivatives as androgen receptor modulator compounds
BRPI0812163A2 (pt)	2007-05-25	2014-12-16	Abbott Gmbh & Co Kg	Compostos heterocíclicos como moduladores positivos do receptor metabotrópico de glutamato 2 (receptor mglu2)
WO2009003009A1 (en)	2007-06-26	2008-12-31	Enanta Pharmaceuticals, Inc.	Substituted pyrrolidine as anti-infectives
JP2010533736A (ja)	2007-07-19	2010-10-28	ハー・ルンドベック・アクチエゼルスカベット	５員複素環アミドおよび関連化合物
EA201000947A1 (ru) *	2007-12-20	2011-02-28	Новартис Аг	Производные тиазола, применимые в качестве ингибиторов киназы pi3
CN101939319A (zh)	2007-12-20	2011-01-05	诺瓦提斯公司	联噻唑衍生物、它们的制备方法以及它们作为药物的用途
ITMI20072396A1 (it)	2007-12-20	2009-06-21	Dachi S R L	"apparato di chiusura di contenitori di materiale biologico"
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

2009
- 2009-08-09 UA UAA201102837A patent/UA104147C2/uk unknown
- 2009-09-08 EP EP09782777.8A patent/EP2331537B1/en active Active
- 2009-09-08 WO PCT/EP2009/061644 patent/WO2010029082A1/en not_active Ceased
- 2009-09-08 SI SI200931344T patent/SI2331537T1/sl unknown
- 2009-09-08 RS RS20150860A patent/RS54476B1/sr unknown
- 2009-09-08 DK DK09782777.8T patent/DK2331537T3/en active
- 2009-09-08 ME MEP-2011-21A patent/ME01284B/me unknown
- 2009-09-08 HR HRP20160014TT patent/HRP20160014T1/hr unknown
- 2009-09-08 PE PE2011000591A patent/PE20110796A1/es active IP Right Grant
- 2009-09-08 UY UY0001032096A patent/UY32096A/es active IP Right Grant
- 2009-09-08 MX MX2011002597A patent/MX2011002597A/es active IP Right Grant
- 2009-09-08 PT PT97827778T patent/PT2331537E/pt unknown
- 2009-09-08 AU AU2009290904A patent/AU2009290904B2/en active Active
- 2009-09-08 BR BRPI0918750A patent/BRPI0918750B8/pt active IP Right Grant
- 2009-09-08 CA CA2734819A patent/CA2734819C/en active Active
- 2009-09-08 EA EA201100447A patent/EA018863B1/ru active Protection Beyond IP Right Term
- 2009-09-08 JP JP2011526479A patent/JP5486601B2/ja active Active
- 2009-09-08 PL PL09782777T patent/PL2331537T3/pl unknown
- 2009-09-08 KR KR1020117005524A patent/KR101290844B1/ko active Active
- 2009-09-08 HU HUE09782777A patent/HUE025884T2/en unknown
- 2009-09-08 GE GEAP200912132A patent/GEP20135991B/en unknown
- 2009-09-08 MY MYPI20110510 patent/MY151556A/en unknown
- 2009-09-08 ES ES09782777.8T patent/ES2560673T3/es active Active
- 2009-09-08 CN CN200980135415.7A patent/CN102149711B/zh active Active
- 2009-09-08 NZ NZ590754A patent/NZ590754A/xx unknown
- 2009-09-08 AR ARP090103437A patent/AR073369A1/es not_active Application Discontinuation
- 2009-09-09 TW TW098130412A patent/TWI453206B/zh active
- 2009-09-09 JO JOP/2009/0334A patent/JO3121B1/ar active
- 2009-09-10 PA PA20098841901A patent/PA8841901A1/es unknown
- 2009-09-10 US US12/556,964 patent/US8227462B2/en active Active
2011
- 2011-01-27 ZA ZA2011/00699A patent/ZA201100699B/en unknown
- 2011-01-31 TN TN2011000053A patent/TN2011000053A1/fr unknown
- 2011-01-31 IL IL210976A patent/IL210976A/en active IP Right Grant
- 2011-02-01 CR CR20110059A patent/CR20110059A/es unknown
- 2011-03-01 MA MA33661A patent/MA32604B1/fr unknown
- 2011-03-07 DO DO2011000070A patent/DOP2011000070A/es unknown
- 2011-03-08 HN HN2011000699A patent/HN2011000699A/es unknown
- 2011-03-09 CL CL2011000504A patent/CL2011000504A1/es unknown
- 2011-03-09 NI NI201100049A patent/NI201100049A/es unknown
- 2011-03-10 CU CU2011000052A patent/CU24000B1/es active IP Right Grant
- 2011-03-10 SV SV2011003853A patent/SV2011003853A/es unknown
- 2011-03-10 EC EC2011010880A patent/ECSP11010880A/es unknown
- 2011-03-17 CO CO11033546A patent/CO6351738A2/es active IP Right Grant
- 2011-04-07 SM SM201100019T patent/SMP201100019B/it unknown
2012
- 2012-06-05 US US13/488,589 patent/US8476268B2/en active Active
2013
- 2013-05-24 US US13/901,930 patent/US8710085B2/en active Active
2014
- 2014-02-27 US US14/192,633 patent/US20140186469A1/en not_active Abandoned
2015
- 2015-12-29 CY CY20151101197T patent/CY1117078T1/el unknown
2018
- 2018-06-06 AR ARP180101520A patent/AR112074A2/es not_active Application Discontinuation
2020
- 2020-11-06 NL NL301071C patent/NL301071I2/nl unknown
- 2020-11-16 NO NO2020037C patent/NO2020037I1/no unknown
- 2020-11-18 HU HUS2000044C patent/HUS2000044I1/hu unknown
- 2020-11-20 LU LU00186C patent/LUC00186I2/fr unknown
- 2020-11-24 CY CY2020037C patent/CY2020037I2/el unknown
- 2020-11-25 LT LTPA2020534C patent/LTC2331537I2/lt unknown
- 2020-11-26 FI FIC20200046C patent/FIC20200046I1/fi unknown

Also Published As

Publication number	Publication date
TN2011000053A1 (en)	2012-09-05
TW201014851A (en)	2010-04-16
US20100105711A1 (en)	2010-04-29
US8227462B2 (en)	2012-07-24
PL2331537T3 (pl)	2016-06-30
IL210976A (en)	2014-09-30
CA2734819C (en)	2017-10-24
BRPI0918750A2 (pt)	2020-08-04
US8710085B2 (en)	2014-04-29
ECSP11010880A (es)	2011-04-29
US20120263712A1 (en)	2012-10-18
DK2331537T3 (en)	2016-01-25
HUS2000044I1 (hu)	2020-12-28
SMP201100019B (it)	2012-01-18
CN102149711B (zh)	2014-09-10
AU2009290904B2 (en)	2012-08-30
NL301071I2 (nl)	2020-12-01
PT2331537E (pt)	2016-03-03
CY2020037I1 (el)	2021-03-12
PE20110796A1 (es)	2011-11-04
NL301071I1 (nl)	2020-11-11
KR101290844B1 (ko)	2013-07-29
DOP2011000070A (es)	2011-03-31
CU24000B1 (es)	2014-06-27
ME01284B (me)	2013-06-20
TWI453206B (zh)	2014-09-21
US20140186469A1 (en)	2014-07-03
UA104147C2 (uk)	2014-01-10
JP2012502080A (ja)	2012-01-26
MX2011002597A (es)	2011-07-21
CL2011000504A1 (es)	2011-07-15
RS54476B1 (sr)	2016-06-30
KR20110038737A (ko)	2011-04-14
JO3121B1 (ar)	2017-09-20
LTPA2020534I1 (lt)	2020-12-28
FIC20200046I1 (fi)	2020-11-26
HK1156305A1 (en)	2012-06-08
HN2011000699A (es)	2013-12-02
CN102149711A (zh)	2011-08-10
AU2009290904A1 (en)	2010-03-18
MA32604B1 (fr)	2011-09-01
LTC2331537I2 (lt)	2022-01-10
LUC00186I2 (sl)	2024-07-01
ZA201100699B (en)	2012-08-29
CU20110052A7 (es)	2011-12-28
CO6351738A2 (es)	2011-12-20
PA8841901A1 (es)	2010-06-28
EA201100447A1 (ru)	2011-10-31
MY151556A (en)	2014-06-13
CY2020037I2 (el)	2021-03-12
BRPI0918750B8 (pt)	2021-05-25
EA018863B1 (ru)	2013-11-29
NO2020037I1 (no)	2020-11-16
AR073369A1 (es)	2010-11-03
AR112074A2 (es)	2019-09-18
NZ590754A (en)	2012-08-31
ES2560673T3 (es)	2016-02-22
SV2011003853A (es)	2011-05-16
HUE025884T2 (en)	2016-05-30
SMAP201100019A (it)	2011-05-06
BRPI0918750B1 (pt)	2020-12-22
WO2010029082A1 (en)	2010-03-18
CA2734819A1 (en)	2010-03-18
JP5486601B2 (ja)	2014-05-07
UY32096A (es)	2010-04-30
GEP20135991B (en)	2013-12-25
EP2331537B1 (en)	2015-10-28
US20140005232A1 (en)	2014-01-02
CY1117078T1 (el)	2017-04-05
NI201100049A (es)	2011-07-26
HRP20160014T1 (hr)	2016-02-12
IL210976A0 (en)	2011-04-28
US8476268B2 (en)	2013-07-02
EP2331537A1 (en)	2011-06-15
CR20110059A (es)	2011-03-28

Publication	Publication Date	Title
HUS2000044I1 (hu)	2020-12-28	Proliferatív betegségek kezelésében alkalmas 1-((5-heteroariltiazol-2-il)-amino-karbonil)pirrolidin-2-karboxamid származékok, mint foszfatidilinozitol 3-kináz (P13K) inhibitorok
IL210494A (en)	2015-08-31	Organic compounds such as smo inhibitors, pharmaceutical preparations containing them and their use in the treatment of cancer
EP2146718A4 (en)	2010-08-11	KINASEHEMMER FOR THE TREATMENT OF MYELOPROLIFERATIVE AND OTHER PROLIFERATIVE DISEASES
IL210802A0 (en)	2011-04-28	Purin derivatives for use in the treatment of fab-related diseases
IL202505A0 (en)	2010-06-30	2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors
IL205747A0 (en)	2010-11-30	Inhibitors of human phosphatidyl-inositol 3-kinase delta
PL2252597T3 (pl)	2014-09-30	Pochodne pirazyny i ich zastosowanie jako inhibitorów kinaz białkowych
IL202317A0 (en)	2010-06-30	Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
MX350761B (es)	2017-09-18	Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
EP2063897A4 (en)	2010-09-29	KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2063896A4 (en)	2010-09-29	KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
PL2349260T3 (pl)	2016-07-29	Inhibitory kinazy Janus do leczenia zespołu suchego oka i innych chorób związanych z okiem
UA105503C2 (uk)	2014-05-26	Похідні 1-аміно-2-циклобутилетилборонової кислоти
AP2011005682A0 (en)	2011-04-30	Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases.
EP2239261A4 (en)	2011-06-08	PYRROLOPYRIMIDINE DERIVATIVE FOR USE AS A PI3K INHIBITOR AND USE THEREOF
ZA201008387B (en)	2012-02-29	Azacarboline derivatives,preparation thereof,and therapeutic use thereof as kinase inhibitors
EP2242501A4 (en)	2011-10-19	THERAPEUTIC INHIBITORS OF PAI-I FUNCTION AND METHODS OF USE
IL202307A0 (en)	2010-06-30	Multikinase inhibitors for use in the treatment of cancer
IL222692A0 (en)	2012-12-31	Piperazinotriazines as pi3k inhibitors for use in the treatment of antiproliferative disorders
IL213136A0 (en)	2011-07-31	Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
ZA201103134B (en)	2012-01-25	(pyrrolidin-2 yl) phenyl derivatives for use in the treatment of pain
HK1140762A (en)	2010-10-22	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
HK1149897A (en)	2011-10-21	Therapeutic inhibitors of pai-1 function methods of their use
HK1147258A (en)	2011-08-05	Inhibitors of human phosphatidyl-inositol 3-kinase delta
HK1136575A (en)	2010-07-02	Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer